Please note: Data collection for the registry has been terminated.

The RenIS registry is a non-interventional post-registration database focused on collection of epidemiological and clinical data of patients with renal cell carcinoma treated with targeted therapies in the Czech Republic. Six targeted anticancer medicaments have been currently observed (sorafenib, sunitinib, temsirolimus, everolimus, bevacizumab, and pazopanib). The project was initiated in June 2007 by the Czech Society for Oncology. Institute of Biostatistics and Analyses Ltd, a spin-off company of the Masaryk University, provides management and other services to this project.

Obtained data allow for monitoring of patients' epidemiological characteristics, treatment regimens used, therapy response, modelling of risk factors effects on patients' survival, and detailed analysis of adverse effects.

The data collection system is primarily oriented on treatment of advanced diseases and disseminated recurrences. However, it contains all necessary items related to the primary tumour. Universal and general data structure of the registry allows for detailed monitoring of any treatment schedule in a logical relationship to the disease progress and respecting effects of factors that significantly affect treatment results.

Primary goals

• Monitoring of total numbers of mRCC patients in the Czech Republic treated with sorafenib, sunitinib, temsirolimus, everolimus, bevacizumab, and pazopanib
• Safety evaluation of the drugs monitored
• Effectiveness evaluation of the treatment and therapy regimens used

Secondary goals

• Analysis of patients' survival in relation to clinical factors observed
• Analysis of patients treated with targeted therapy in relation to Czech population-based reference data